Form 4: Rocket Pharmaceuticals Officer Sells Shares to Cover Tax Obligations

Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold 1,582 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On May 16, 2025, Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold 1,582 shares of common stock.
• The sale was executed at a price of $6.528 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Schwartz directly owns 236,056 shares of Rocket Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction for tax purposes and doesn't reflect a significant change in the executive's holdings or outlook.

Industry Context

This is a routine transaction where an executive sells shares to cover tax obligations related to equity compensation. It's a common practice and doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders, as it is a small percentage of the total outstanding shares and is related to tax obligations.

Key Dates

Keywords

Rocket Pharmaceuticals, Jonathan David Schwartz, stock sale, Form 4, insider trading, RCKT, RSU, tax obligations